EBQ:IST-3: Difference between revisions
(EBQ) |
|||
| Line 16: | Line 16: | ||
==Clinical Question== | ==Clinical Question== | ||
Can use of fibrinolytics for acute ischemic stroke be extended to a wider range of patients up to 6 hours? | |||
==Conclusion== | ==Conclusion== | ||
Revision as of 06:08, 4 November 2014
incomplete Journal Club Article
IST-3 collaborative group. "The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.". Lancet. 2012. 379(9834):2352 - 2363.
PubMed Full text
PubMed Full text
Clinical Question
Can use of fibrinolytics for acute ischemic stroke be extended to a wider range of patients up to 6 hours?
Conclusion
Major Points
Inclusion Criteria
Exclusion Criteria
Interventions
Outcome
Primary Outcomes
Secondary Outcomes
Subgroup analysis
Criticisms
Funding
UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden, Swedish Heart Lung Fund, The Foundation of Marianne and Marcus Wallenberg, Polish Ministry of Science and Education, the Australian Heart Foundation, Australian National Health and Medical Research Council (NHMRC), Swiss National Research Foundation, Swiss Heart Foundation, Assessorato alla Sanita, Regione dell'Umbria, Italy, and Danube University.